Literature DB >> 26223296

Assessment of anti-Müllerian hormone levels in premenopausal patients with systemic lupus erythematosus.

A A Gasparin1, L Souza2, M Siebert3, R M Xavier2, R M S Chakr2, P E Palominos2, J C T Brenol2, O A Monticielo2.   

Abstract

OBJECTIVE: The ovarian reserve of patients with systemic lupus erythematosus (SLE) may be affected by disease activity and medication use. Studies have found that patients with SLE have similar fertility rates as healthy women of the same age. The goal of the present study was to investigate the ovarian reserve of patients with SLE by measuring anti-Müllerian hormone (AMH) levels, and compare it to that of healthy controls.
METHOD: This was a case-control study performed on 80 premenopausal women, of whom 40 fulfilled the 1997 American College of Rheumatology (ACR) criteria for SLE and 40 healthy controls paired by oral contraceptive use. Serum concentrations of AMH in peripheral venous blood were measured using a human AMH ELISA kit (CUSABIO, Wuhan, China).
RESULTS: AMH serum levels did not differ between patients with SLE and controls (22.79 ± 17.32 ng/ml versus 21.41 ± 16.22 ng/ml, respectively, p = 0.7), even after adjusting for age (21.03 ± 2.074 ng/ml versus 23.97 ± 2.71 ng/ml; p = 0.5). AHM levels were not significantly correlated with disease duration (r = 0.2; p = 0.3), body mass index (r = 0.2; p = 0.2) and disease activity (SLEDAI (r = 0.1; p = 0.7)) and damage indices (SLICC (r = 0.1; p = 0.7)). No associations were found between AMH and ethnicity, current smoking, as well as current or prior use of cyclophosphamide and other immunosuppressants.
CONCLUSION: In this cross-sectional study, women with SLE demonstrated similar AMH levels as healthy controls, suggesting preserved ovarian reserve in this population.
© The Author(s) 2015.

Entities:  

Keywords:  Anti-Müllerian hormone; ovarian reserve; systemic lupus erythematosus

Mesh:

Substances:

Year:  2015        PMID: 26223296     DOI: 10.1177/0961203315598246

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

Review 1.  Does APS Impact Women's Fertility?

Authors:  Cecilia Beatrice Chighizola; Maria Gabriella Raimondo; Pier Luigi Meroni
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

2.  Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve.

Authors:  Clara Di Mario; Luca Petricca; Maria Rita Gigante; Angelina Barini; Antonella Barini; Valentina Varriano; Annamaria Paglionico; Paola Cattani; Gianfranco Ferraccioli; Barbara Tolusso; Elisa Gremese
Journal:  Endocrine       Date:  2018-10-15       Impact factor: 3.633

Review 3.  Sexual and reproductive health in rheumatic disease.

Authors:  Monika Østensen
Journal:  Nat Rev Rheumatol       Date:  2017-07-06       Impact factor: 20.543

Review 4.  Infertility - Prevention and Management.

Authors:  Emily C Somers; Wendy Marder
Journal:  Rheum Dis Clin North Am       Date:  2017-03-14       Impact factor: 2.670

5.  Anti-Müllerian hormone in African-American women with systemic lupus erythematosus.

Authors:  Meghan Angley; Jessica B Spencer; S Sam Lim; Penelope P Howards
Journal:  Lupus Sci Med       Date:  2020-11

Review 6.  Systemic lupus erythematosus: strategies to improve pregnancy outcomes.

Authors:  Yuriko Yamamoto; Shigeru Aoki
Journal:  Int J Womens Health       Date:  2016-07-08

7.  Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study.

Authors:  Shefali Khanna Sharma; Siddharth Jain; Pooja Bahl; Pragna Potturi; Manish Rathi; Shankar Naidu; Naresh Sachdeva; Varun Dhir; Sanjay Jain
Journal:  Arthritis Res Ther       Date:  2020-08-14       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.